ReviewJournal of endocrinological investigation2017
Immunotherapy for type 1 diabetes.
Review in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Treg gene signatures predict and measure type 1 diabetes trajectory.JCI insight · 2019Trial
- Oral health and salivary inflammatory markers in children and adolescents with type 1 diabetes: A cross-sectional study.Journal of endocrinological investigation · 2026Article
- Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art.Pharmacological reports : PR · 2025Review
- Diabetes as an independent risk factor for severe inflammatory bowel disease: evidence from an inflammation-metabolism-liver coupling framework.Frontiers in endocrinology · 2025Article
- Benefits and Hurdles of Pancreatic β-Cell Replacement.Stem cells translational medicine · 2022Review
- Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges.Stem cell research & therapy · 2022Review
- The unfulfilled potential of mucosal immunization.The Journal of allergy and clinical immunology · 2022Review
- Diabetes type 1: Can it be treated as an autoimmune disorder?Reviews in endocrine & metabolic disorders · 2021Review
- Prevalence of gestational diabetes and its association with stillbirth, preterm birth, macrosomia, abortion and cesarean delivery: a national prevalence study of 11 provinces in Iran.Journal of preventive medicine and hygiene · 2021Article
- A cross-sectional study of the knowledge and screening practices of diabetes among adults in a south western Nigerian city.Journal of preventive medicine and hygiene · 2021Article
- Effect of alginate matrix engineered to mimic the pancreatic microenvironment on encapsulated islet function.Biotechnology and bioengineering · 2021Article
- A comprehensive integrated post-GWAS analysis of Type 1 diabetes reveals enhancer-based immune dysregulation.PloS one · 2021Article
- Adipose‑derived mesenchymal stem cells ameliorate dibutyltin dichloride‑induced chronic pancreatitis by inhibiting the PI3K/AKT/mTOR signaling pathway.Molecular medicine reports · 2020Article
- PPARs and the Development of Type 1 Diabetes.PPAR research · 2020Review
- Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun.World journal of diabetes · 2019Article
- A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.Journal of diabetes research · 2019Article
- Article
- Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice.Diabetologia · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough many approaches have been tested to overcome the insulin dependence caused by the pancreatic β-cells destruction observed in individuals affected by type 1 diabetes (T1D), medical research has largely failed to halt the onset or to reverse T1D.
methodsIn this work, the state of the art of immunotherapy will be examined, and the most important achievement in the field will be critically discussed. Particularly, we will focus on the clinical aspect, thus avoiding the tedious preclinical work done in NOD mice, which has been so poorly translated to the bedside.
conclusionsStem cell therapies achieved thus this far the most promising results, while immune ablation and standard immunosuppressants did not maintain the premises of preclinical results. The next step will be to generate a feasible and safe clinical approach in order to cure the thousands of patients affected by T1D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.